Mesa Laboratories, Inc. (MLAB)

From the record

Mesa Laboratories, Inc.'s filings since 2017 show 5 warning events of 2 kinds: an auditor change (8-K item 4.01, 4 times, the latest 2025-06-06); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-06-14) (its current reports).

From the record

Mesa Laboratories, Inc.'s 10 filed years say what it did: revenue went from $94 million in fiscal 2017 to $249 million in fiscal 2026, up 11.5% a year; it rose in 8 of 9 years; the deepest fall was 1% from fiscal 2023 to fiscal 2024; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-03-31, Mesa Laboratories, Inc.'s diluted share count grew about 1.3% a year, and dividends and buybacks returned about 8% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 7 sales (3 under scheduled 10b5-1 plans) and 5 purchases of their own stock on the open market in the year to 2026-10-29, buying about $1 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-03-31, Mesa Laboratories, Inc. earned about 4 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 37 cents per dollar of everything the company owns. Leverage: it owed about 56 cents per dollar of assets, and net share issuance: its share count grew 2.7% over the year (the filed statements).

From the record

Mesa Laboratories, Inc.'s standing among 17 graded names in its industry family: revenue of $249 million in fiscal 2026 ranks in the bottom 41% by size; a net margin of 2.7% ranks in the top 50%; revenue growth of 4.4% a year over the last 3 filed years ranks in the top 26% (its annual reports).

From the record

Mesa Laboratories, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kadia, Siddhartha (President and CEO, as filed), filing under that title since 2026-04-24, 7 months (bottom 3% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6.4 years (top 50%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 46%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Mesa Laboratories, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $27 million against debt of $68 million leaves -9.5% of its assets as net cash, bottom 41% of its family; cash from operations less capital spending is 15.9% of revenue (top 44%); a gross margin of 63.5% (top 15%); research spending of 8.2% of revenue (top 50%) (its annual report).

From the record

Mesa Laboratories, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 4.4% a year over the last three filed years against 11.5% over all 10, slowing (bottom 44% of its family); the newest year grew 3.4% (top 50%); research spending grew -0.3% a year (bottom 34%); capital spending grew -10.6% a year (bottom 38%) (its annual reports). Mesa Laboratories, Inc. reported 2 product lines in fiscal 2026: Product at $203 million (82%), Service at $46 million (18%); 2 of 2 grew against the year before (its annual report).

From the record

Mesa Laboratories, Inc.'s newest year against its own record: revenue of $249 million in fiscal 2026 came in 1.4% below the $253 million its prior three years' pace pointed to (bottom 37% of its family); net income of $7 million against a prior three-year average of $85 million (top 10%); a net margin of 2.7% against -39.3% before (top 10%) (its annual reports).